ArticleClinical and vaccine immunology : CVI2007
Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp.
Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Potential antigenic targets used in immunological tests for diagnosis of tegumentary leishmaniasis: A systematic review.PloS one · 2021Pooled it
- Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis.Memorias do Instituto Oswaldo Cruz · 2016Pooled it
- A systematic review of high quality diagnostic tests for Chagas disease.PLoS neglected tropical diseases · 2012Pooled it
- ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.BMC infectious diseases · 2010Pooled it
- High molecular weight proteins of Trypanosoma cruzi reduce cross-reaction with Leishmania spp. in serological diagnosis tests.BioMed research international · 2014Trial
- Stage-InformedMicroorganisms · 2026Article
- Glycocalyx-Driven Immunomodulation in Trypanosoma cruzi: Structures, Host Responses, Diagnostic and Therapeutic Targeting.Parasite immunology · 2026Review
- Article
- Article
- Evaluation of four chimeric Trypanosoma cruzi recombinant antigens for serological diagnosis of chronic Chagas disease in dogs: a phase II study.Parasites & vectors · 2025Article
- K-mer-based approach for serodiagnostic antigen discovery in Chagas disease using unassembled sequencing reads.PLoS neglected tropical diseases · 2025Article
- Chagas and Vector-Borne Disease Exposures in an Indigenous Community in the Ecuadorian Amazon: A Retrospective Study.The American journal of tropical medicine and hygiene · 2025Article
- Evaluation of a Novel Tc-24 Recombinant Antigen ELISA for Serologic Detection of Trypanosoma cruzi Infection in Dogs: A Pilot Study.Veterinary medicine and science · 2025Article
- Chronic Chagas Disease in the Brazilian Amazon: Serological Survey, Clinical Follow-Up, and Associated Risk Factors.The American journal of tropical medicine and hygiene · 2025Article
- Extracellular Vesicles Derived from Trypanosomatids: The Key to Decoding Host-Parasite Communication.International journal of molecular sciences · 2025Review
- Comparison of Four Chimeric Antigens and Commercial Serological Assays for the Diagnosis of Trypanosoma cruzi Infection.The American journal of tropical medicine and hygiene · 2025Article
- The diagnostic value of two antigenic domains derived from theFrontiers in microbiology · 2025Article
- A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms.International journal of molecular sciences · 2024Article
- Characterization of NovelInternational journal of molecular sciences · 2024Article
- Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.